Complete your CAR T cell workflow with off-the-shelf lentiviral vectors

Designed to support point-of-care CAR T cell manufacturing in hematological disease applications.

Logo

Complete your CAR T cell workflow with off-the-shelf lentiviral vectors

arrow leftarrow right

Point-of-care (PoC) manufacturing brings CAR T cell production closer to the patient. For clinical centers building PoC workflows in hematological disease applications, securing access to a suitable lentiviral vector (LVV) can be one of the practical barriers between process setup and manufacturing readiness.

At Miltenyi Biotec, we provide GMP-grade off-the-shelf LVVs for the gene engineering step in CAR T cell manufacturing. Beyond the vector, we offer a range of technologies and services to support your team. These include fast and consistent automated manufacturing processes as well as analytics, training, documentation, and GMP implementation, supporting you on your way to PoC CAR T cell manufacturing.

Our off-the-shelf LVV portfolio includes three second-generation CAR constructs comprising one or two antigen-recognition domains and a shared intracellular architecture with a 4-1BB co-stimulatory domain and CD3 zeta signaling domain.

Designed to fit your CAR T cell manufacturing workflow

Off-the-shelf CAR LVVs are designed to be integrated into CAR T cell manufacturing workflows on the CliniMACS Prodigy® Platform. See how the vector fits into the workflow, from sample preparation to final formulation and fill, with analytics (including starting material testing, in-process control, and release testing) supported by the MACSQuant® Analyzer 16.

Ready when your workflow is ready

Access off-the-shelf LVVs for the gene engineering step in local CAR T cell manufacturing workflows.

Manufactured for clinical readiness

Off-the-shelf LVVs are supported by regulatory documentation and preclinical data packages to help with development and regulatory preparation.

Built on defined quality standards

Manufactured in Germany under a clinical-grade quality management system, with regular third-party audits supporting quality and compliance.

Advanced support that goes beyond the vector

Miltenyi Biotec can support the workflow around the LVVs with automated manufacturing technologies, training, documentation, and services tailored to your site.

Clinical employees in clean room attire setting up a cell manufacturing process on the CliniMACS Prodigy

Miltenyi Biotec's CAR LVVs in hematological disease studies

CAR T cell approaches continue to advance the treatment of hematological malignancies. Explore published studies using Miltenyi Biotec CAR LVVs for CAR T cell manufacturing, from CD19-targeted therapies to dual-targeting approaches. Beyond the clinical findings, they report key manufacturing data, such as transduction efficiency, product characteristics, expansion, viability, and manufacturing success.

Publication thumbnail for “Human CART22.19 therapy in pediatric B-ALL: insights from a named-patient cohort” in Journal for ImmunoTherapy of Cancer

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort

Mast, A. -S. et al. (2026) J. Immunother. Cancer 14: e013901.

This case series describes nine pediatric patients with relapsed or refractory B-ALL who received CART22.19 within a named-patient program in Germany. The tandem CD19-CD22 CAR T cell product was manufactured from autologous or donor-derived T cells using the CliniMACS Prodigy Platform and a lentiviral vector provided by Miltenyi Biotec. The final products showed a median transduction efficiency of 53.7% at harvest, indicating successful CAR gene transfer.

Go to publication

Publication thumbnail for “Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refrisk first relapse or in very-high-risk first relapse” in Blood Advances

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse

Del Bufalo, F. et al. (2025) Blood Adv. 9: 5091–5102.

This phase 1/2 trial reports point-of-care manufacturing of CD19-CAR_Lenti cells for 19 pediatric or young adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia or very-high-risk first relapse. All target doses were successfully manufactured on the CliniMACS Prodigy Platform. The final products showed a median frequency of 42.91% CAR-positive cells and a median vector copy number of 0.7 copies per cell, key parameters for product characterization.

Go to publication

Tailored analytical solutions

For characterization and molecular testing

Support your CAR T cell manufacturing workflow with analytical solutions for CAR T cell characterization as well as vector copy number and RCL testing.

Scientist looking at a sample, standing in front of a flow cytometer, performing cell and gene therapy analytics on the MACSQuant Analyzer 16 flow cytomer, CliniMACS Prodigy in a clean room in the background

Services

People operating the CliniMACS Prodigy® cell manufacturing platform in a cleanroom laboratory

Cell manufacturing enabling package

Fast-track CAR T cell manufacturing implementation at your site with training, consultation, documentation, and workflow support. CMEP helps your team move from project initiation to clinical manufacturing in just 12 to 18 months.

Explore CMEP

Looking for off-the-shelf CAR LVVs?

Want to discuss how the off-the-shelf CAR lentiviral vectors could fit into your point-of-care CAR T cell workflow? Fill in your details and we will get in touch.

Attention

The medical device and therapy related information on this website is intended for access by healthcare professionals only and their request.

By clicking "Accept" you are confirming that you are a healthcare professional and have read and agreed to the information above. If you are not a healthcare professional, please

click here

to be redirected to www.miltenyibiotec.com.